Body Trimmer for abdominal obesity: does it help with weight loss?

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Participants with abdominal obesity will take Amway BODY TRIMMER daily for 12 weeks and visit the clinic every four weeks for tests and checkups. The study compares two dose levels to see if dose affects weight loss indicators. Eligibility requires adults 30–65 with abdominal obesity, BMI ≥24, and no medications that could affect metabolism. The trial is sponsored by Amway China R&D and conducted at a Shanghai hospital.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male and female participants aged 30 to 65 years (inclusive), with an equal male-to-female enrollment ratio.
* Presence of abdominal obesity, defined as: waist circumference ≥90 cm in males or ≥85 cm in females; or waist-to-hip ratio (WHR) ≥0.90 in males or ≥0.85 in females.
* Body mass index (BMI) ≥24.0 kg/m².
* No use of any prescription drugs, over-the-counter medications, traditional Chinese medicines, or health supplements that may affect blood pressure, lipid profile, glucose metabolism, endocrine function, or intestinal microbiota within 1 month prior to screening.
* No documented history of allergy or intolerance to any components of the investigational product.
* Able to fully understand the study objectives, procedures, and potential adverse reactions, voluntarily provides written informed consent, and is willing and able to complete the 12-week intervention and scheduled follow-up assessments.

Exclusion Criteria:

* A history of clinically significant hepatic or renal dysfunction (mild simple non-alcoholic fatty liver disease is excluded), untreated or managed thyroid disorders including hyperthyroidism and hypothyroidism, or any cardiovascular or cerebrovascular disease requiring ongoing medical intervention.
* Diagnosis of any chronic or active gastrointestinal or intestinal disease within 1 year prior to screening (e.g., chronic diarrhea, chronic constipation), regardless of disease status at enrollment.
* Use of any weight-loss interventions within 3 months before screening, including weight-loss prescription drugs, over-the-counter products, traditional Chinese medicines, oral or injectable health supplements, or weight-loss devices. Examples include but are not limited to: semaglutide, liraglutide, phentermine, orlistat, amylase inhibitors, L-carnitine preparations, prebiotic enzyme supplements, and chitosan capsules.
* Screening laboratory values showing total cholesterol (TC) \>10.34 mmol/L or triglycerides (TG) \>5.7 mmol/L.
* Excessive alcohol consumption, defined as a weekly pure alcohol intake exceeding 210 g in males or 140 g in females (referencing the 2024 Guidelines for the Prevention and Treatment of Metabolic-Associated Fatty Liver Disease).
* Uncontrolled hypertension with systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg at screening (without antihypertensive medication).
* Known allergy or hypersensitivity to any ingredients of the investigational product.
* Pregnancy or breastfeeding status at screening.
* Participants or their partners with a planned pregnancy, sperm donation, or egg donation from the time of informed consent through 3 months after the final study product administration, who are unwilling to practice effective non-study contraception during this period.
* Any form of intentional dietary restriction undertaken from 30 days prior to informed consent up to the enrollment day.
* Presence of psychiatric disorders or any other medical or social conditions deemed inappropriate for study participation by the investigator's clinical judgment.

Where it's running

• Shanghai Fengxian District Central Hospital
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Principal Investigator
• Email: shfxec@163.com
• Phone: 18018820470

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nitraria Retusa Infusion for Clozapine-Related Metabolic Side Effects in Treatment-Resistant Schizophrenia

  A daily Nitraria retusa leaf infusion is tested for 90 days to see if it helps with metabolic side effects in people with treatment-resistant schizophrenia who are taking clozapine.

  Recruiting Faculty of Medicine, Sousse · Sousse · NCT07817069

• Long-term walnut intake and brain function in abdominally obese adults

  This trial tests whether eating walnuts for 24 weeks improves brain blood flow and insulin sensitivity, and whether it boosts thinking and appetite control in adults with abdominal obesity.

  Recruiting Maastricht University Medical Center · Maastricht, Limburg · NCT07422220

• Electrical stimulation plus isometric exercise to improve blood flow in resistant high blood pressure

  This will try whether adding upper‑thoracic electrical stimulation (TENS) and isometric exercise to usual blood pressure medications can lower blood pressure and improve peripheral blood flow in men and women aged 50–60 with resistant hypertension.

  Recruiting Cairo University · Port Said, Port Said Governorate · NCT07383220

• Immersive virtual reality plus plyometric workouts for abdominal obesity in teenage girls

  This will test whether adding immersive virtual reality to plyometric workouts helps 13–18-year-old girls with abdominal obesity improve waist measurements and lung function over three months.

  Recruiting New Ismailia National University · Ismailia · NCT07092228

• Tesamorelin plus exercise to improve physical function in older adults with HIV

  This trial will test whether adding the drug tesamorelin to a structured exercise program helps improve strength and physical performance in adults aged 50–80 living with HIV who have abdominal obesity and early frailty.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Aurora, Colorado and 1 other locations · NCT06554717

• Acupuncture to reduce weight and belly fat in people with prediabetes

  This trial will try acupuncture versus a sham procedure in adults with prediabetes and combined obesity to see if it helps them lose weight, shrink their waist, and improve blood sugar and cholesterol.

  Recruiting Guang'anmen Hospital of China Academy of Chinese Medical Sciences · Beijing · NCT06359418

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.